This Article Abstract Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Beckett, J R Articles by Michaelson, J S Search for Related Content PubMed PubMed Citation Articles by Beckett, J R Articles by Michaelson, J S

Analysis of benefit:risk ratio and mortality reduction for the UK Breast Screening Programme

¹ Regional Medical Physics Department, Newcastle General Hospital, Newcastle-upon-Tyne NE4 6BE, UK and ² Departments of Pathology and Radiology, Massachusetts General Hospital and Department of Pathology, Harvard Medical School, Boston, MA USA

View larger version (14K): [in a new window]   Figure 1. Benefit:risk ratio (BRR) vs compressed breast thickness for the current NHSBSP regimen. BRR in terms of years of life (YOL) is shown as circles (); BRR in terms of breast cancer mortality is shown as triangles ().

View larger version (16K): [in a new window]   Figure 2. Reduction (R) in breast cancer mortality () and years of life lost (YOLL) to breast cancer () vs compressed breast thickness for the current NHSBSP regimen.

View larger version (17K): [in a new window]   Figure 3. Benefit:risk ratio in terms of breast cancer mortality (BRR(d)) vs age at first screen for regimens with final screens at ages 64 years (), 66 years (), 68 years () and 70 years (). The interval between successive screens is 3 years in each case.

View larger version (18K): [in a new window]   Figure 4. Benefit:risk ratio in terms of years of life lost to breast cancer (BRR(y)) vs age at first screen for regimens employing a final screen at age 64 years (), 66 years (), 68 years () and 70 years (). The interval between successive screens is 3 years in each case.

View larger version (16K): [in a new window]   Figure 5. Reduction in breast cancer mortality (R(d)) vs age at first screen for regimens employing a final screen at age 64 years (), 66 years (), 68 years () and 70 years (). The interval between successive screens is 3 years in each case.

View larger version (16K): [in a new window]   Figure 6. Reduction in the number of years of life lost to breast cancer (R(y)) vs age at first screen for regimens employing a final screen at age 64 years (), 66 years (), 68 years () and 70 years (). The interval between successive screens is 3 years in each case.

View larger version (18K): [in a new window]   Figure 7. Mean reduction in breast cancer mortality (R(d)) per screen vs age at first screen for regimens employing a final screen at age 64 years (), 66 years (), 68 years () and 70 years (). The interval between successive screens is 3 years in each case.

View larger version (18K): [in a new window]   Figure 8. Mean reduction in the number of years of life lost to breast cancer (R(y)) per screen vs age at first screen for regimens employing a final screen at age 64 years (), 66 years (), 68 years () and 70 years (). The interval between successive screens is 3 years in each case.

View larger version (14K): [in a new window]   Figure 9. Benefit:risk ratio in terms of breast cancer mortality (BRR(d)) vs interval between successive screens for screening in the age ranges 50–64 years () and 50–70 years ().

View larger version (14K): [in a new window]   Figure 10. Benefit:risk ratio in terms of years of life lost to breast cancer (BRR(y)) vs interval between successive screens for screening in the age ranges 50–64 years () and 50–70 years ().

View larger version (13K): [in a new window]   Figure 11. Reduction in breast cancer mortality (R(d)) vs interval between successive screens for screening in the age ranges 50–64 years () and 50–70 years ().

View larger version (13K): [in a new window]   Figure 12. Reduction in the number of years of life lost to breast cancer (R(y)) vs interval between successive screens for screening in the age ranges 50–64 years () and 50–70 years ().

View larger version (15K): [in a new window]   Figure 13. Mean reduction in breast cancer mortality (R(d)) per screen vs interval between successive screens for screening in the age ranges 50–64 years () and 50–70 years ().

View larger version (13K): [in a new window]   Figure 14. Mean reduction in the number of years of life lost to breast cancer (R(y)) per screen vs interval between successive screens for screening in the age ranges 50–64 years () and 50–70 years ().